Mr. Stefano Picone reports

CONAVI MEDICAL ANNOUNCES RESULTS FROM ITS ANNUAL GENERAL MEETING OF SHAREHOLDERS AND ADOPTION OF AMENDMENTS TO OMNIBUS EQUITY INCENTIVE PLAN

Conavi Medical Corp. has released the results of its annual general meeting of shareholders held virtually on March 31, 2025, as well as the adoption of amendments to the company's stock option plan.

A total of 30,075,712 common shares were voted in connection with the meeting, representing approximately 67.97 per cent of the issued and outstanding common shares of the company.

Each of the seven nominees listed in the management information circular of the company dated Feb. 18, 2025, namely, Thomas Looby, Aaron Davidson, Craig Podolsky, Robert D. Mitchell, Susan Allen, Cathy Steiner and Anthony J. Giovinazzo, was elected as a director of the company for the ensuing year or until his or her successor is elected or appointed.

In addition, Conavi Medical reports that an ordinary resolution approving the appointment of PricewaterhouseCoopers LLP as the company's auditor for the ensuing year and to authorize the directors to fix the auditor's remuneration was passed at the meeting.

Further, an ordinary resolution of disinterested shareholders of the company was passed approving the amendment of the company's omnibus equity incentive plan to remove certain restrictions on the participation of company directors, executive officers and other insiders (as a group). The company believes that the removal of the restrictions on insider participation in the omnibus equity incentive plan (as a group) will provide the company with greater flexibility to continue to attract, retain and motivate directors and executive officers, while providing room for future growth. Importantly, the total maximum number shares available for issuance under the omnibus equity incentive plan, being 8,850,017 common shares, has not changed and remains in place in respect of all awards under the omnibus equity incentive plan. This number was fixed based on the number of shares equal to 20 per cent of the issued and outstanding shares upon closing of the company's reverse takeover transaction on Oct. 11, 2024.

The amendments to the company's omnibus equity incentive plan remain subject to the approval of the TSX Venture Exchange. Options granted pursuant to the amendments to the company's omnibus equity incentive plan may not be exercised until TSX-V approval has been received.

About Conavi Medical Corp.

Conavi Medical is focused on designing, manufacturing and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight hybrid system is the first system to combine both intravascular ultrasound and optical coherence tomography to enable simultaneous and co-registered imaging of coronary arteries. The Novasight hybrid system has 510(k) clearance from the U.S. Food and Drug Administration, and regulatory approval for clinical use from Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare.

We seek Safe Harbor.